Precigen (NASDAQ: PGEN) Form 144 covers 32,739 common shares for sale

Rhea-AI Filing Summary

Precigen, Inc. filed a notice relating to the sale of common stock on NASDAQ through Fidelity Brokerage Services LLC. The filing lists 32,739 common securities with an aggregate value of $224,589.54 and references total related common securities of 358,035,247. It also shows that the securities to be sold were originally acquired via restricted stock vesting as compensation from the issuer on 04/30/2020 (12,472 units), 03/19/2021 (4,039 units), and 05/12/2022 (16,228 units).

Key Figures

Common securities covered: 32,739 Aggregate value: $224,589.54 Related common securities total: 358,035,247 +4 more

7 metrics

Common securities covered 32,739 Amount listed under common securities information associated with the sale

Aggregate value $224,589.54 Value associated with the 32,739 common securities

Related common securities total 358,035,247 Total common securities figure shown in the securities information section

Date reference 08/06/2026 Key date listed in the securities information for the common securities

Restricted stock vesting units 2020 12,472 Units acquired on 04/30/2020 via restricted stock vesting as compensation

Restricted stock vesting units 2021 4,039 Units acquired on 03/19/2021 via restricted stock vesting as compensation

Restricted stock vesting units 2022 16,228 Units acquired on 05/12/2022 via restricted stock vesting as compensation

Key Terms

Form 144, Restricted Stock Vesting, Compensation, Securities To Be Sold

4 terms

Form 144 regulatory

"144: Filer Information | | | 144: Filer Information"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

Restricted Stock Vesting financial

"Common | 04/30/2020 | Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Compensation financial

"12472 | 04/30/2020 | Compensation Common | 03/19/2021 |"

Securities To Be Sold regulatory

"NASDAQ 144: Securities To Be Sold Common | 04/30/2020"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 01:18 PM Accepted by SEC EDGAR 08/06/2026 - 01:17 PM Learn about SEC filing dates

FAQ

What does Precigen (PGEN) disclose in this Form 144 filing?

Precigen discloses a planned sale of common stock on NASDAQ through Fidelity Brokerage Services LLC, covering 32,739 common securities with an aggregate value of $224,589.54, along with related background on how these securities were acquired.

How many Precigen (PGEN) common securities are covered in the Form 144?

The Form 144 lists 32,739 common securities. It also references a larger related total of 358,035,247 common securities, providing context for the holdings associated with this planned stock sale disclosure.

What is the aggregate value of the Precigen (PGEN) securities in this Form 144?

The aggregate value of the common securities covered is $224,589.54. This value is tied to the 32,739 common securities identified in the filing as part of the securities information for the planned sale.

Through which broker will Precigen (PGEN) securities be sold according to the Form 144?

The filing identifies Fidelity Brokerage Services LLC, located at 900 Salem Street, Smithfield, RI 02917, as the broker involved for the common stock sale to be executed on the NASDAQ market.

How were the Precigen (PGEN) securities in this Form 144 originally acquired?

The securities were acquired via restricted stock vesting as compensation from the issuer on three dates: 04/30/2020 (12,472 units), 03/19/2021 (4,039 units), and 05/12/2022 (16,228 units), all categorized as compensation.

What key dates are associated with the Precigen (PGEN) Form 144 filing?

Key dates include an indicated date of 08/06/2026 in the securities information section and acquisition dates of 04/30/2020, 03/19/2021, and 05/12/2022 for restricted stock vesting compensation awards.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	32739	224589.54	358035247	08/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	04/30/2020	Restricted Stock Vesting	Issuer			12472	04/30/2020	Compensation
Common	03/19/2021	Restricted Stock Vesting	Issuer			4039	03/19/2021	Compensation
Common	05/12/2022	Restricted Stock Vesting	Issuer			16228	05/12/2022	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)